Trademark: 90618201
Word
ANAKURIA
Status
Dead
Status Code
606
Status Date
Monday, March 18, 2024
Serial Number
90618201
Mark Type
4000
Filing Date
Thursday, April 1, 2021
Published for Opposition
Tuesday, June 20, 2023
Abandoned Date
Monday, March 18, 2024

Trademark Owner History
Anakuria Therapeutics, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations and substances for the prevention, treatment and diagnosis of cancer, diabetes, and heart disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of neurodegenerative diseases, namely, Alzheimer's disease, Parkinson's disease, and Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of immune disorders, namely, psoriasis, rheumatoid arthritis, lupus, Crohn's disease, inflammatory bowel disease, and multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of metabolic, endocrine, cardiovascular, oncological, gastrointestinal, musculoskeletal, nephrological, mitochondrial, autoimmune, and neurological related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of rare genetic diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of Leigh's syndrome, Friedrich's ataxia, lymphangioleiomyomatosis (LAM) and tuberous sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of obesity and obesity related diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of age-related diseases; pharmaceutical preparations and substances for modulating the catabolic or anabolic response to nutrients; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of any disease related to muscle wasting diseases and conditions, including, cachexia, sarcopenia and muscle wasting due to prolonged immobilization; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting caloric intake and absorption; pharmaceuticals, therapeutics and nutraceuticals for use as active ingredients in foods, namely, dietary supplements; pharmaceuticals, therapeutics and nutraceuticals for use as food additives for medical purposes, namely, amino acids; dietetic substances for medical purposes, namely, dietetic foods such as dietary beverage supplements adapted for medical use; nutritional additives for medical purposes, namely, amino acids; pharmaceutical preparations and substances for the modulation of appetite, namely, appetite suppressants and satiety inducers
42 Pharmaceutical research and development; drug development and discovery services; medical and scientific research; providing medical and scientific research information in the field of pharmaceuticals
The name(s), portrait(s), and/or signature(s) shown in the mark does not identify a particular living individual.

Trademark Events
Mar 18, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Mar 18, 2024
Abandonment - No Use Statement Filed
Aug 15, 2023
Noa E-Mailed - Sou Required From Applicant
Jun 20, 2023
Official Gazette Publication Confirmation E-Mailed
Jun 20, 2023
Published For Opposition
May 31, 2023
Notification Of Notice Of Publication E-Mailed
May 15, 2023
Approved For Pub - Principal Register
Nov 14, 2022
Report Completed Suspension Check Case Still Suspended
May 17, 2022
Notification Of Letter Of Suspension E-Mailed
May 17, 2022
Letter Of Suspension E-Mailed
May 17, 2022
Suspension Letter Written
May 16, 2022
Teas/Email Correspondence Entered
May 16, 2022
Correspondence Received In Law Office
May 16, 2022
Teas Response To Office Action Received
Nov 16, 2021
Notification Of Non-Final Action E-Mailed
Nov 16, 2021
Non-Final Action E-Mailed
Nov 16, 2021
Non-Final Action Written
Nov 16, 2021
Assigned To Examiner
Jul 9, 2021
New Application Office Supplied Data Entered
Apr 5, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24